Get the Stockscreener App
0.4087
9.66%
-0.0437
After Hours:
.41
0.0013
+0.32%
Bioxcel Therapeutics Inc stock is traded at $0.4087, with a volume of 1.96M.
It is down -9.66% in the last 24 hours and down -42.50% over the past month.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
See More
Previous Close:
$0.4524
Open:
$0.46
24h Volume:
1.96M
Relative Volume:
3.63
Market Cap:
$19.76M
Revenue:
$1.38M
Net Income/Loss:
$-179.05M
P/E Ratio:
-0.0575
EPS:
-7.11
Net Cash Flow:
$-155.03M
1W Performance:
-19.71%
1M Performance:
-42.50%
6M Performance:
-77.17%
1Y Performance:
-89.52%
1-Day Range:
$0.40
$0.4661
1-Week Range:
$0.40
$0.50
52-Week Range:
$0.40
$4.17
Bioxcel Therapeutics Inc Stock (BTAI) Company Profile
Name
Bioxcel Therapeutics Inc
Sector
Industry
Phone
203-643-8060
Address
555 LONG WHARF DRIVE, NEW HAVEN, CT
Compare BTAI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BTAI
Bioxcel Therapeutics Inc
|
0.4087 | 19.76M | 1.38M | -179.05M | -155.03M | -6.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.13 | 120.56B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
750.22 | 82.44B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
616.55 | 36.87B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.07 | 32.64B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.39 | 28.38B | 3.30B | -501.07M | 1.03B | -2.1146 |
Bioxcel Therapeutics Inc Stock (BTAI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-21-24 | Downgrade | UBS | Buy → Neutral |
| Aug-15-23 | Downgrade | Mizuho | Buy → Neutral |
| Jul-17-23 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-10-23 | Downgrade | Jefferies | Buy → Hold |
| Dec-01-22 | Upgrade | Goldman | Sell → Neutral |
| Jul-07-22 | Initiated | Mizuho | Buy |
| Apr-06-22 | Reiterated | BofA Securities | Buy |
| Nov-15-21 | Downgrade | Goldman | Neutral → Sell |
| Apr-09-21 | Initiated | Berenberg | Buy |
| Feb-01-21 | Initiated | UBS | Buy |
| Oct-30-20 | Initiated | Goldman | Buy |
| Sep-02-20 | Initiated | Jefferies | Buy |
| Aug-17-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-04-20 | Initiated | Guggenheim | Buy |
| Apr-01-20 | Initiated | BofA/Merrill | Buy |
| Feb-26-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-08-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-12-19 | Initiated | SunTrust | Buy |
View All
Bioxcel Therapeutics Inc Stock (BTAI) Latest News
BioXcel Therapeutics announces pricing of $7M public offering - MSN
BioXcel Therapeutics stock hits 52-week low at $0.5 By Investing.com - Investing.com Canada
BioXcel Therapeutics Prices of $7 Million Public Offering - citybiz
BioXcel Therapeutics stock hits 52-week low at $0.5 - Investing.com India
BioXcel Therapeutics announces $7M public offering - Hartford Business Journal
BioXcel Prices New Offering - Baystreet.ca
BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering - GlobeNewswire
BioXcel Therapeutics Announces $7M Public Offering at $0.48 Per Share with Warrants | BTAI Stock News - StockTitan
BioXcel Therapeutics amends credit agreement, issues new warrants - Investing.com
BioXcel Therapeutics amends credit agreement, issues new warrants By Investing.com - Investing.com Canada
BioXcel Therapeutics Announces Proposed Public Offering - GlobeNewswire
BioXcel Therapeutics Announces Proposed Public Offering - Benzinga
BioXcel Therapeutics Launches Public Offering to Fund Critical Clinical Trials | BTAI Stock News - StockTitan
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q3 2024 Earnings Call Transcript - MSN
BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Lags Revenue Estimates - MSN
BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights: Strategic Trials and ... - Yahoo Finance
BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights: Strategic Trials and Financial Adjustments - GuruFocus.com
BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights: Strategic Trials and ... By GuruFocus - Investing.com Canada
BioXcel Therapeutics Inc. (BTAI) Quarterly 10-Q Report - Quartzy
BioXcel Therapeutics Reports Q3 2024 Financial Results - TipRanks
500: Something went wrong - Investing.com India
Earnings call: BioXcel Therapeutics reports Q3 2024 financials - Investing.com
Earnings call: BioXcel Therapeutics reports Q3 2024 financials By Investing.com - Investing.com UK
BioXcel Therapeutics earnings beat by $0.19, revenue fell short of estimates - Investing.com Canada
BioXcel Therapeutics Inc Reports Q3 2024 Earnings: Net Revenue a - GuruFocus.com
BioXcel Therapeutics Reports Third Quarter 2024 Financial Results - GlobeNewswire
BioXcel Q3 Revenue Drops 37%, but Net Loss Narrows Significantly to $13.7M | BTAI Stock News - StockTitan
Critical Survey: Emergent BioSolutions (NYSE:EBS) vs. BioXcel Therapeutics (NASDAQ:BTAI) - Defense World
What To Expect From BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings - GuruFocus.com
BioXcel Therapeutics (BTAI) Set to Announce Earnings on Thursday - Defense World
What's Next: BioXcel Therapeutics's Earnings Preview - Benzinga
BioXcel advances trials for acute agitation treatments - Investing.com India
BioXcel advances trials for acute agitation treatments By Investing.com - Investing.com UK
BioXcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer's Dementia - The Manila Times
BioXcel Therapeutics Advances Pivotal Phase 3 Trials of - GlobeNewswire
BioXcel's Phase 3 Breakthrough: First Patient Enrolled in Critical Agitation Treatment Trial | BTAI Stock News - StockTitan
BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024 - GlobeNewswire
Will BioXcel Therapeutics, Inc. (BTAI) Report Negative Q3 Earnings? What You Should Know - MSN
ROSEN, TRUSTED AND TOP RANKED INVESTOR COUNSEL, Encourages BioXcel Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionBTAI - Marketscreener.com
BioXcel Therapeutics to Present at ThinkEquity Conference - The Manila Times
Pre-market Movers: EVOK, HCTI, GLUE, MNPR... - RTTNews
BioXcel Therapeutics (NASDAQ:BTAI) PT Lowered to $5.00 - Defense World
BioXcel announces defense grant to UNC to fund study for treating acute stress disorder - MSN
BioXcel Therapeutics partners with UNC for ASD trial By Investing.com - Investing.com Australia
BioXcel Therapeutics partners with UNC for ASD trial - Investing.com India
BioXcel Therapeutics Announces U.S. Department of Defense - GlobeNewswire
Bioxcel Therapeutics Inc Stock (BTAI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.61%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):